Xiaoxiao Wang; Huixin Liu; Jinlei Qi; Fangfang Zeng; Lijun Wang; Peng Yin; Feng Liu; Hongbo Li; Yunning Liu; Jiangmei Liu; Lai Wei; Xiaofeng Liang; Yu Wang; Huiying Rao; Maigeng Zhou; Xiaoxiao Wang; Huixin Liu; Jinlei Qi; Fangfang Zeng; Lijun Wang; Peng Yin; Feng Liu; Hongbo Li; Yunning Liu; Jiangmei Liu; Lai Wei; Xiaofeng Liang; Yu Wang; Huiying Rao; Maigeng Zhou

doi:10.46234/ccdcw2023.128

[1]

Yu CS, Chen YD, Chang SS, Tang JH, Wu JL, Lin CH. Exploring and predicting mortality among patients with end-stage liver disease without cancer: a machine learning approach. Eur J Gastroenterol Hepatol 2021;33(8):1117 − 23. http://dx.doi.org/10.1097/MEG.0000000000002169.

[2]

Tao YC, Chen EQ. Clinical application of stem cell in patients with end-stage liver disease: progress and challenges. Ann Transl Med 2020;8(8):564. http://dx.doi.org/10.21037/atm.2020.03.153.

[3]

Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021;134(7):783 − 91. http://dx.doi.org/10.1097/CM9.0000000000001474.

[4]

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390(10100):1211 − 59. http://dx.doi.org/10.1016/S0140-6736(17)32154-2.

[5]

Tang X, Allain JP, Wang H, Rong X, Chen J, Huang K, et al. Incidence of hepatitis B virus infection in young Chinese blood donors born after mandatory implementation of neonatal hepatitis B vaccination nationwide. J Viral Hepat 2018;25(9):1008 − 16. http://dx.doi.org/10.1111/jvh.12901.

[6]

Liu ZQ, Mao XH, Jiang YF, Cai N, Jin L, Zhang TJ, et al. Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China. Cancer Med 2019;8(12):5787 − 99. http://dx.doi.org/10.1002/cam4.2477.

[7]

Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Chin J Hepatol 2019;27(12):938 − 61. http://dx.doi.org/10.3760/cma.j.issn.1007-3418.2019.12.007.

[8]

Shan S, You H, Niu JQ, Shang J, Xie W, Zhang YX, et al. Baseline characteristics and treatment patterns of the patients recruited to the China registry of hepatitis B. J Clin Transl Hepatol 2019;7(4):322 − 8. http://dx.doi.org/10.14218/JCTH.2019.00052.

[9]

The Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 2022;7(5):396 − 415. http://dx.doi.org/10.1016/S2468-1253(21)00472-6.

[10]

Sun YY, Wang YH, Li MM, Cheng KL, Zhao XY, Zheng Y, et al. Long-term trends of liver cancer mortality by gender in urban and rural areas in China: an age-period-cohort analysis. BMJ Open 2018;8(2):e020490. http://dx.doi.org/10.1136/bmjopen-2017-020490.

[11]

Li M, Wang ZQ, Zhang L, Zheng H, Liu DW, Zhou MG. Burden of cirrhosis and other chronic liver diseases caused by specific etiologies in China, 1990–2016: findings from the global burden of disease study 2016. Biomed Environ Sci 2020;33(1):1 − 10. http://dx.doi.org/10.3967/bes2020.001.

[12]

Song C, Lv J, Liu Y, Chen JG, Ge ZJ, Zhu J, et al. Associations between hepatitis B virus infection and risk of all cancer types. JAMA Netw Open 2019;2(6):e195718. http://dx.doi.org/10.1001/jamanetworkopen.2019.5718.

[13]

Wang MJ, Wang YT, Feng XS, Wang RJ, Wang YM, Zeng HM, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese national cancer center. Int J Infect Dis 2017;65:15 − 21. http://dx.doi.org/10.1016/j.ijid.2017.09.003.

[14]

Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology 2020;72(5):1605 − 16. http://dx.doi.org/10.1002/hep.31173.

[15]

Fan XQ, Zhang B, He Y, Zhou XL, Zhang YY, Ma L, et al. Burden of disease due to cancer — China, 2000–2019. China CDC Wkly 2022;4(15):306 − 11. http://dx.doi.org/10.46234/ccdcw2022.036.

[16]

Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, et al. The impact of hepatitis C virus outside the liver: evidence from Asia. Liver Int 2017;37(2):159 − 72. http://dx.doi.org/10.1111/liv.13272.

[17]

Mei X, Lu HZ. Prevalence, diagnosis, and treatment of hepatitis C in mainland China. Glob Health Med 2021;3:270 − 5. http://dx.doi.org/10.35772/ghm.2021.01080.